度-QTc建模以支持Fezolinetant的临床开发
Jace C Nielsen1, Masako Saito2, Xuegong Wang1
1Astellas Pharma Global Development, Inc., IL, USA.
Clinical pharmacology in drug development
|October 19, 2025
概括
费索利内坦 (Fezolinetant) 是一种治疗更年期血管运动症状的药物,它不会导致显著的QT延长. 这一发现支持其安全性,消除了彻底QT研究的需要.
科学领域:
- 药理学 药理学是指药理学的学科.
- 心血管安全心血管安全
- 神经内分泌学神经内分泌学
背景情况:
- 费索利内坦是被批准用于治疗更年期的血管运动症状的选择性神经素-3受体抗剂.
- 它通过调节温度调节中心的神经元活动来起作用.
研究的目的:
- 在3期试验之前评估与fezolinetant相关的QT延长风险.
- 为了确定是否需要进行彻底的QT (TQT) 研究以提交监管要求.
主要方法:
- 使用1期上升剂量研究的数据进行了度-QTc (C-QTc) 分析.
- 在健康参与者中,分析包括高达900毫克的单剂量和高达720毫克的多次每日剂量.
- 遵循了ICH E14指南的建议.
主要成果:
- 在C-QTc分析中发现,在治疗或超治疗剂量的fezolinetant时,没有临床相关的QT延长.
- 建模结果表明缺乏显著的心血管风险.
结论:
- 费索利内坦不构成临床相关的QT延长风险.
- 安全数据支持放弃彻底QT (TQT) 研究的要求.
相关概念视频
Drug Concentration Versus Time Correlation
1.9K
The plasma drug concentration-time curve is a crucial tool in pharmacokinetics, representing the drug's concentration in plasma at different time intervals post-administration. This curve illustrates the drug's journey from absorption into the systemic circulation, distribution to body tissues, and eventual elimination through excretion or biotransformation.
Two pivotal parameters are the minimum effective concentration (MEC) and the minimum toxic concentration (MTC). The MEC is the...
Two pivotal parameters are the minimum effective concentration (MEC) and the minimum toxic concentration (MTC). The MEC is the...
1.9K
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations
204
Gentamicin, an aminoglycoside antibiotic, is commonly administered via intermittent intravenous infusion to treat severe infections. An intermittent one-hour infusion of gentamicin, administered at eight-hour intervals, allows for precise control of plasma drug concentrations, minimizing toxicity while ensuring therapeutic efficacy. Pharmacokinetic principles govern the dynamics of plasma concentrations and can be mathematically described using specific equations.The plasma drug concentration...
204
Dosage Regimens: Partial Pharmacokinetic Parameters
132
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
132
One-Compartment Open Model for IV Bolus Administration: Estimation of Elimination Rate Constant, Half-Life and Volume of Distribution
798
The one-compartment open model is a simplified approach used in pharmacokinetics to understand the distribution and elimination of a drug administered through an intravenous bolus. This model assumes rapid drug dispersal throughout the body and elimination using a first-order process. Key pharmacokinetic parameters, such as the elimination rate constant (k), half-life (t1/2), and the apparent volume of distribution (Vd), can be estimated from this model. The elimination rate is calculated...
798
Time Course of Drug Effect
2.6K
The progression of a drug's impact can be analyzed by examining both the concentration-time course and the effect-time course. The concentration-time course is determined by the drug's half-life and is influenced by factors such as its pharmacokinetics, including absorption, distribution, metabolism, and elimination. The effect of the drug is often related to its concentration in the plasma and is calculated using the maximum drug effect and the plasma concentration that generates 50...
2.6K
Clinically Relevant Drug Product Specifications: Methods of Establishment
173
Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...
173


